A New Era in Pancreatic Cancer Treatment: Daraxonrasib Shakes Up the Landscape

As Pancreatic Cancer Awareness Month is marked this November, a breakthrough in targeted therapy is offering a significant leap forward in a field that has seen limited progress for decades. The investigational drug, daraxonrasib (Rasonque), has demonstrated an unprecedented doubling of survival in patients with previously treated metastatic pancreatic cancer, according to results from the global phase 3 RASolute 302 trial (NCT06625320), heralding a new era for one of the most challenging malignancies we face.¹

For more than 4decades, the KRAS gene mutation, present in over 90% of pancreatic cancer cases, has been notoriously “undruggable,” thwarting countless research efforts. This reality has contributed to the grim prognosis associated with pancreatic ductal adenocarcinoma (PDAC). However, the recent results from RASolute 302 are set to change the treatment paradigm.

The trial data, which were met with a standing ovation when presented at the 2026 American Society of Clinical Oncology Annual Meeting, are nothing short of historic. In a study of 500 patients with previously treated metastatic disease, daraxonrasib, a first-in-class, oral, multiselective RAS(ON) inhibitor, has shown remarkable efficacy compared withstandard-of-care chemotherapy.

Key Findings From the RASolute 302 Trial:

• Overall survival (OS): The trial’s primary endpoint was met with a near doubling of median OS, from 6.7 months (95% CI, 5.8-8.0) for patients on chemotherapy (n = 252) to 13.2 months (95% CI, 10.0-not estimable) for those treated with daraxonrasib (n = 248). This represents a 60% reduction in the risk of death(HR, 0.40; 95% CI, 0.30-0.53; P = 4.6×10^–11).
• Progression-free survival (PFS): Patients receiving daraxonrasib experienced a median PFS of 7.2 months (95% CI, 5.7-7.5), a significant improvement over the 3.6 months (95% CI, 2.9-4.2) observed in the chemotherapy arm (HR, 0.49; 95% CI, 0.38-0.64; P = 5.2×10^–8).
• Overall response rate (ORR): The ORR for the daraxonrasib arm (n = 237) was 31.6%, nearly tripling the ORR of 11.2% seen with standard chemotherapy (n = 241; P < .0001).

From a clinical standpoint, daraxonrasib not only offers a significant survival benefit but also a manageable safety profile. While adverse effects (AEs) such as skin rash, stomatitis, and diarrhea were common, they were generally manageable. Notably, patients treated with daraxonrasib were far less likely to discontinue treatment due to severe AEs than those undergoing chemotherapy.

Moreover, the FDA granted daraxonrasib in combination with chemotherapy a breakthrough therapy designation for frontline metastatic PDAC in September 2026; the drug received full FDA approval in August 2026.^2,3

The success of daraxonrasib is a monumental step forward, proving that even the most stubborn oncogenic drivers can be targeted. Daraxonrasib is poised to become the new standard of care for second-line treatment of metastatic pancreatic cancer.

This Pancreatic Cancer Awareness Month, the news of daraxonrasib provides a powerful message of hope. Daraxonrasib and its success are a testament to the persistence of the research community and a reminder that continued investment in understanding the fundamental biology of this disease can, and does, lead to practice-changing breakthroughs. As the field looks to the future, ongoing trials are already exploring daraxonrasib’s potential in combination with other agents and in earlier stages of the disease, promising to further build on this remarkable achievement.

References

1. Wolpin BM, Wainberg ZA, Hendifar AE, et al. Daraxonrasib, a RAS(ON) multi-selective inhibitor vs chemotherapy in previously treated metastatic pancreatic adenocarcinoma (mPDAC): primary and final analysis from the phase 3 RASolute 302 study. Presented at: 2026 American Society of Clinical Oncology Annual Meeting; May 29-June 2,2026; Chicago, IL.
2. FDA approves first in class targeted therapy for metastatic pancreatic cancer. News release. FDA. August 26, 2026. Accessed October 2, 2026. https://www.fda.gov/news-events/press-announcements/fda-approves-first-class-targeted-therapy-metastatic-pancreatic-cancer
3. Revolution Medicines announces US FDA breakthrough therapy designation for Rasonque (daraxonrasib) in combination with chemotherapy for first-line metastatic pancreatic cancer. News release. Revolution Medicines, Inc. September 14, 2026. Accessed October 2, 2026. https://www.revmed.com/media/news/13431/revolution-medicines-announces-u-s-fda-breakthrough-therapy-designation-for-rasonquetm-daraxonrasib-in-combination-with-chemotherapy-for-first-line-metastatic-pancreatic-cancer